Mark Halvorson

Array ( [id] => 14870791 [patent_doc_number] => 20190285637 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-19 [patent_title] => BIOMARKERS FOR GASTRIC CANCER AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/431174 [patent_app_country] => US [patent_app_date] => 2019-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19756 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -47 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16431174 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16979011 [patent_doc_number] => 20210223248 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-22 [patent_title] => BIOMARKERS, USES THEREOF FOR SELECTING IMMUNOTHERAPY INTERVENTION, AND IMMUNOTHERAPY METHODS [patent_app_type] => utility [patent_app_number] => 15/734205 [patent_app_country] => US [patent_app_date] => 2019-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41902 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -58 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15734205 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16778061 [patent_doc_number] => 20210115139 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-22 [patent_title] => PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, CONTAINING CD300E INHIBITOR AS ACTIVE INGREDIENT [patent_app_type] => utility [patent_app_number] => 17/041293 [patent_app_country] => US [patent_app_date] => 2019-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3966 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17041293 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15294291 [patent_doc_number] => 20190390281 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-26 [patent_title] => CHARACTERIZATION OF PRE-CANCER BIOMARKER FOR PROGNOSTIC SCREEN [patent_app_type] => utility [patent_app_number] => 16/414746 [patent_app_country] => US [patent_app_date] => 2019-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18106 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 6 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16414746 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16793244 [patent_doc_number] => 20210123061 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-29 [patent_title] => METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY DISEASE OR DISORDER [patent_app_type] => utility [patent_app_number] => 17/052656 [patent_app_country] => US [patent_app_date] => 2019-05-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25543 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17052656 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19105814 [patent_doc_number] => 11958895 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-04-16 [patent_title] => Anti-influenza neuraminidase monoclonal antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 17/049400 [patent_app_country] => US [patent_app_date] => 2019-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 20965 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17049400 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14833463 [patent_doc_number] => 20190275132 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-12 [patent_title] => DIVALENT VACCINE COMPOSITIONS AND THE USE THEREOF FOR TREATING TUMORS [patent_app_type] => utility [patent_app_number] => 16/398334 [patent_app_country] => US [patent_app_date] => 2019-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5294 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16398334 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17611595 [patent_doc_number] => 20220153874 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-19 [patent_title] => HUMAN-DERIVED ANTI-(POLY-GA) DIPEPTIDE REPEAT (DPR) ANTIBODY [patent_app_type] => utility [patent_app_number] => 17/050353 [patent_app_country] => US [patent_app_date] => 2019-04-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49806 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17050353 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16622790 [patent_doc_number] => 20210041443 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-11 [patent_title] => WNT6 AS GLIOBLASTOMA ONCOGENIC BIOMARKER, AND USES OF INHIBITORS THEREOF [patent_app_type] => utility [patent_app_number] => 17/050693 [patent_app_country] => US [patent_app_date] => 2019-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9860 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17050693 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16949458 [patent_doc_number] => 20210208149 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-08 [patent_title] => METHODS FOR CELL PROFILING [patent_app_type] => utility [patent_app_number] => 17/047668 [patent_app_country] => US [patent_app_date] => 2019-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5847 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 125 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17047668 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15586497 [patent_doc_number] => 20200069783 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-05 [patent_title] => COMPOSITIONS AND METHODS OF IDENTIFYING TUMOR SPECIFIC NEOANTIGENS [patent_app_type] => utility [patent_app_number] => 16/381791 [patent_app_country] => US [patent_app_date] => 2019-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22737 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 130 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16381791 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17053611 [patent_doc_number] => 20210263045 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-26 [patent_title] => PREDICTION AND TREATMENT OF IMMUNOTHERAPEUTIC TOXICITY [patent_app_type] => utility [patent_app_number] => 17/045482 [patent_app_country] => US [patent_app_date] => 2019-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18851 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17045482 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14836227 [patent_doc_number] => 20190276514 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-12 [patent_title] => THERAPEUTIC AND DIAGNOSTIC CLONED MHC-UNRESTRICTED RECEPTOR SPECIFIC FOR THE MUC1 TUMOR ASSOCIATED ANTIGEN [patent_app_type] => utility [patent_app_number] => 16/366885 [patent_app_country] => US [patent_app_date] => 2019-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16132 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16366885 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15708763 [patent_doc_number] => 20200101147 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-02 [patent_title] => POLYPEPTIDE VACCINE [patent_app_type] => utility [patent_app_number] => 16/358400 [patent_app_country] => US [patent_app_date] => 2019-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39400 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16358400 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14838901 [patent_doc_number] => 20190277851 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-12 [patent_title] => METHODS OF DETECTING CANCER [patent_app_type] => utility [patent_app_number] => 16/356879 [patent_app_country] => US [patent_app_date] => 2019-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11266 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16356879 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17822706 [patent_doc_number] => 11427644 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-30 [patent_title] => Dual antigen-induced bipartite functional complementation [patent_app_type] => utility [patent_app_number] => 16/289798 [patent_app_country] => US [patent_app_date] => 2019-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 40 [patent_no_of_words] => 40020 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 316 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16289798 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17822706 [patent_doc_number] => 11427644 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-30 [patent_title] => Dual antigen-induced bipartite functional complementation [patent_app_type] => utility [patent_app_number] => 16/289798 [patent_app_country] => US [patent_app_date] => 2019-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 40 [patent_no_of_words] => 40020 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 316 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16289798 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17005351 [patent_doc_number] => 20210236512 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-05 [patent_title] => CLOZAPINE FOR THE TREATMENT OF A IMMUNOGLOBULIN DRIVEN B CELL DISEASE [patent_app_type] => utility [patent_app_number] => 16/965244 [patent_app_country] => US [patent_app_date] => 2019-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48777 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16965244 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16629006 [patent_doc_number] => 20210047659 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-18 [patent_title] => SYSTEM AND METHOD FOR INDUCING CLUSTERS OF GENE REGULATORY PROTEINS TARGETED TO SPECIFIC GENOMIC LOCI [patent_app_type] => utility [patent_app_number] => 16/964052 [patent_app_country] => US [patent_app_date] => 2019-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8788 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16964052 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14583951 [patent_doc_number] => 20190219584 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-18 [patent_title] => AUTOANTIBODY BIOMARKERS OF OVARIAN CANCER [patent_app_type] => utility [patent_app_number] => 16/245822 [patent_app_country] => US [patent_app_date] => 2019-01-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20260 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16245822 [rel_patent_id] =>[rel_patent_doc_number] =>)